Phase III
The Janssen Pharmaceutical Companies, part of Johnson & Johnson, announced results from two long-term Phase III trials of esketamine nasal spray.
It has been one year since Mitsubishi Tanabe Pharma America’s Radicava was approved as the first treatment for amyotrophic lateral sclerosis (ALS) in more than 20 years. Since its approval, MTPA has been aggressive in its efforts to get the medication in the hands of ALS patients.
AstraZeneca’s add-on asthma treatment Fasenra has failed a second Phase III trial this month.
Novo Nordisk announced results from its second Phase IIIa clinical PIONEER 2 trial.
On April 5, San Francisco’s Eidos Therapeutics closed on a Series B financing round worth $64 million. Now the company has filed with the U.S. Securities and Exchange Commission (SEC) to raise $115 million through an initial public offering (IPO).
Following the long holiday weekend, three pharma companies began the week with good news as the U.S. Food and Drug Administration awarded their therapies with Priority Review Status.
After Axovant Sciences’ spectacular clinical trial failure in September 2017, the company has been reorganizing. Today it announced it had completed that reorganization by adding to its executive team and Scientific Advisory Board.
A combination of Genentech’s Tecentriq and chemotherapy enabled some lung cancer patients in a Phase III trial to live significantly longer than chemotherapy alone. The latest report continues the string of successes the company has had with Tecentriq, an anti-PD-L1 immunotherapy.
It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
AstraZeneca and its research-and-development unit MedImmune, announced positive overall survival (OS) data for its Phase III PACIFIC trial of Imfinzi (durvalumab) in patients with unresectable Stage III non-small cell lung cancer (NSCLC).
PRESS RELEASES